Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) Debt to Equity (2020 - 2022)

Anika Therapeutics (ANIK) has disclosed Debt to Equity for 7 consecutive years, with $0.02 as the latest value for Q2 2022.

  • Quarterly Debt to Equity fell 74.36% to $0.02 in Q2 2022 from the year-ago period, while the trailing twelve-month figure was $0.02 through Jun 2022, down 74.36% year-over-year, with the annual reading at $0.02 for FY2021, 68.72% down from the prior year.
  • Debt to Equity for Q2 2022 was $0.02 at Anika Therapeutics, roughly flat from $0.02 in the prior quarter.
  • The five-year high for Debt to Equity was $0.17 in Q2 2020, with the low at $0.01 in Q3 2021.
  • Average Debt to Equity over 3 years is $0.06, with a median of $0.05 recorded in 2020.
  • The sharpest move saw Debt to Equity crashed 66.07% in 2021, then tumbled 83.24% in 2022.
  • Over 3 years, Debt to Equity stood at $0.05 in 2020, then plummeted by 68.72% to $0.02 in 2021, then rose by 0.33% to $0.02 in 2022.
  • According to Business Quant data, Debt to Equity over the past three periods came in at $0.02, $0.02, and $0.02 for Q2 2022, Q1 2022, and Q4 2021 respectively.